Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of genes and expression products thereof in ischemic cardiomyopathy

A technology for ischemic cardiomyopathy and expression products, applied in the field of biomedicine, can solve the complicated and cumbersome problems of ICM diagnosis

Inactive Publication Date: 2019-05-17
AFFILIATED HOSPITAL OF TAISHAN MEDICAL UNIVERSITY +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no suitable biomarkers for the diagnosis of ICM in clinical practice. The diagnosis of ICM is complicated and cumbersome, so early and rapid diagnosis and treatment of ICM are particularly important.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of genes and expression products thereof in ischemic cardiomyopathy
  • Use of genes and expression products thereof in ischemic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Screening for Gene Markers Related to Ischemic Cardiomyopathy

[0051] 1. Sample collection

[0052] Left ventricular tissue and blood samples were collected from patients with ischemic cardiomyopathy, and left ventricular tissue and blood samples from patients with non-ischemic cardiomyopathy who died without cardiomyopathy.

[0053] 1) Collection of blood samples

[0054] Blood samples from 25 normal people and 30 patients with ischemic cardiomyopathy were collected and stored at -20°C for future use.

[0055] 2) Collection of tissue samples

[0056] Left ventricular tissue samples were collected from 20 patients with ischemic cardiomyopathy and from 8 non-cardiomyopathy deaths.

[0057] Inclusion criteria for patients with ischemic cardiomyopathy: determined with reference to Burch's (1972) diagnostic criteria for ICM and the New York Heart Association (NYHA) cardiac function grading criteria, all of which are cardiac function (NYHA) class II-IV and Pat...

Embodiment 2

[0081] Example 2 QPCR sequencing to verify the differential expression of COLGALT2 or GTF2E1 gene

[0082] 1. Large sample QPCR verification of COLGALT2 or GTF2E1 gene.

[0083] 2. RNA extraction

[0084] 1) Extraction of tissue RNA

[0085] Tissue RNA was extracted by the TRIZOL method, and the steps were the same as in Example 1.

[0086] 2) Extraction of blood RNA

[0087]Take fresh blood, add 3 times the volume of red blood cell lysate, mix well, place at room temperature for 10 minutes, and centrifuge at 10,000 rpm for 1 minute; discard the supernatant and collect the white blood cell pellet. Add 1 ml TRIZOL per 100-200 μl blood collected leukocyte pellet. Centrifuge at 12,000 rpm at 4°C for 10 minutes, and take the supernatant. Add 200 μl of chloroform, and the subsequent steps are the same as in Example 1.

[0088] 3. QPCR detection

[0089] 1) Primer design

[0090] Primers were designed according to the gene sequences of COLGALT2, GTF2E1 and GADPH. For genes w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses use of genes and expression products thereof in ischemic cardiomyopathy. The invention discloses use of COLGALT2 or GTF2E1 in the preparation of a product for diagnosing ischemic cardiomyopathy, and a product for detecting an expression level of COLGALT2 or GTF2E1. The invention also discloses use of COLGALT2 or GTF2E1 in constructing a computational model for predicting ischemic cardiomyopathy.

Description

technical field [0001] The invention relates to the field of biomedicine, and relates to the application of a gene and its expression product in ischemic cardiomyopathy. The gene is COLGALT2 or GTF2E1. Background technique [0002] Ischemic cardiomyopathy (ICM) is the end stage of coronary atherosclerotic heart disease, which is caused by diffuse fibrosis and hyperplasia of cardiomyocytes when the heart is in a state of myocardial ischemia for a long time. It is characterized by heart failure, gradual enlargement of the atrioventricular cavity, and arrhythmia. Ischemic cardiomyopathy often precedes or suggests a history of myocardial infarction in most patients. There are still many objective factors affecting the long-term prognosis of ischemic cardiomyopathy. Such as electrolyte disturbance, degree of coronary artery disease, left ventricular end-diastolic diameter, arrhythmia, left ventricular ejection function, etc. The pathogenesis of ischemic cardiomyopathy is closel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68
Inventor 赵强李正美李元民江科赵洋
Owner AFFILIATED HOSPITAL OF TAISHAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com